IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Jerussi et al. Confirmation No.: 4423

Serial No.: 10/720,134 Art Unit: 1621

Filed: November 25, 2003 Examiner: Paul A. Zucker

For: DERIVATIVES OF VENLAFAXINE Attorney Docket No: 4821-531-999

AND METHODS OF PREPARING CAM: 208423-999528 AND USING THE SAME

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to Applicants' duty of disclosure under 37 C.F.R. § 1.56, enclosed is a list of one (1) reference for the Examiner's review and consideration. The reference is listed on the enclosed "List of References Cited by Applicant." A copy of this reference is also enclosed herein. The reference provided herein is a copy of an *Ex parte Quayle* office action issued in U.S. Application No. 11/091,518, which claims priority to this application.

Identification of the foregoing reference is not to be construed as an admission of Applicants or Attorneys for Applicants that such is a publication or available as "prior art" against the subject application. Applicants respectfully request that the Examiner review the reference and make it of record by completing and returning the enclosed List of References.

LAI-2974093v1 - 1 -

The \$180.00 fee believed due for the submission of this paper will be paid by EFS Web. If any additional fees are required, however, the Director is authorized to charge such fees to Jones Day Deposit Account No. 50-3013.

Respectfully submitted, September 11, 2008 L0209 Date (Ltd. Recog. No.) Jones Day For: Anthony M. Insogna (Reg. No. 35,203)

Jones Day

12265 El Camino Real, Suite 200

San Diego, CA 92130 (858) 314-1200

Enclosure